Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Video Presentations



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


Fluidigm Access Array Technology Helps Identify Mutations in Leukemia

Fluidigm Access Array Technology Fluidigm has announced that MLL Munich Leukemia Laboratory ( has used the company's Access ArrayTM technology to help  it uncover mutations in over 80 percent of chronic myelomonocytic leukemia (CMML) patients, providing new insights into the molecular heterogeneity of the disease. MLL researchers applied the unique properties of the Fluidigm Access Array System to prepare the samples and barcode the amplicons for next-generation deep-sequencing using 454 sequencing technology.

In a Letter to the Editor entitled "Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance" published in the February 22, 2011 issue of Nature LEUKEMIA ( magazine, researchers found mutations in 81.5 percent of CMML patients providing new insights into the molecular heterogeneity of leukemia. Researchers found that besides alterations in TET2, CBL, ASXL1 and the RAS pathway, EZH2 is targeted by various types of frameshift and point mutations. EZH2 mutations constitute a novel poor prognostic risk group and, moreover, had the strongest clinical impact of all markers analyzed thus far. Therefore, researchers suggest that EZH2 mutational status should be taken into account in future clinical studies of CMML.

"Fluidigm's Access Array System was used to prepare the samples into a total of 1782 bar-coded amplicons in a fast, easy process. Being able to automate this type of procedure with Fluidigm's microfluidic technology provides researchers with the ability to make large, in-depth studies possible, practical and affordable," said Gajus Worthington, Fluidigm president and CEO. "We're excited and gratified that Fluidigm technology could help MLL with their discovery and hope it can lead to new ways to understand and treat leukemia."

Fluidigm develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including chips and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.

For more information, please visit

* Fluidigm, the Fluidigm logo, BioMark, Access Array, Dynamic Array, Digital Array, FC1, Topaz, and NanoFlex are trademarks or registered trademarks of Fluidigm Corporation


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners


Exhibitions & Events